| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Tubulin; natural diterpenoids
7-Xylosyl-10-Deacetyltaxol B targets cancer cells through antitumor mechanisms. As a taxol derivative, it may share the mechanism of action of paclitaxel, which involves stabilization of microtubules and inhibition of mitotic spindle dynamics, leading to cell cycle arrest and apoptosis. The compound inhibits various types of cancer, including breast, ovarian, and lung cancer. |
|---|---|
| ln Vitro |
Water decoctions from the leaves of Taxus cuspidata are used in traditional Chinese medicine to treat cancer, suggesting that water soluble constituents from these leaves may possess anticancer properties. Interestingly, hydrophilic paclitaxel derivatives, as opposed to paclitaxel itself, can be detected by high pressure liquid chromatography in water decoctions from these leaves. The remainder extracts, which are free of paclitaxel and hydrophilic paclitaxel derivatives, from the T. cuspidata leaves were investigated for antitumor activity in vivo and in vitro for the first time in this study. EE80B, 7-xylosyl-10-deacetylpaclitaxel and 7-xylosyl-10-deacetylpaclitaxel C displayed the most antitumor activity in vivo. However, in vitro studies with tumor cell lines showed that EE80B had a significantly smaller antitumor effect than paclitaxel. We hypothesize that water decoctions from T. cuspidata leaves exhibit antitumor effects in vivo, which may be aided by the activation of specific host mechanisms (e.g. stimulation of antitumor immunity) which are not present in vitro[1].
In vitro, 7-Xylosyl-10-Deacetyltaxol B has antitumor activity. It can inhibit the growth of S180 sarcoma cells. As a taxol derivative, it may exhibit cytotoxic activity against various cancer cell lines through microtubule stabilization. However, detailed in vitro activity data including IC₅₀ values against specific cancer cell lines have not been extensively published. |
| ln Vivo |
In vivo, 7-Xylosyl-10-Deacetyltaxol B can inhibit the growth of S180 sarcoma. As a taxol derivative with antitumor activity, it may have potential for cancer treatment. The compound is extracted from Taxus species, which are the source of paclitaxel and related taxanes. However, detailed in vivo study results have not been extensively published.
|
| Enzyme Assay |
In vitro cytotoxicity assays for 7-Xylosyl-10-Deacetyltaxol B typically involve treating cancer cell lines with varying concentrations of the compound for 48-72 hours, followed by assessment of cell viability using MTT, SRB, or CCK-8 assays. IC₅₀ values are calculated from dose-response curves. Microtubule polymerization assays can be used to evaluate the compound's mechanism of action. The compound's structure can be confirmed by NMR and MS. Purity ≥98%.
|
| Cell Assay |
In vitro cellular assays for 7-Xylosyl-10-Deacetyltaxol B typically involve evaluation of cytotoxicity in cancer cell lines including breast, ovarian, and lung cancer cell lines. Cells are treated with serial dilutions of the compound and cell viability is assessed using MTT or similar assays. Cell cycle analysis and apoptosis detection can be performed by flow cytometry. Microtubule stabilization can be assessed by immunofluorescence staining.
|
| Animal Protocol |
In vivo animal experiments for 7-Xylosyl-10-Deacetyltaxol B have been conducted in S180 sarcoma models. Tumor-bearing mice are treated with the compound and tumor growth is monitored. Endpoints include tumor volume measurement, tumor weight, and survival analysis. The compound inhibits S180 sarcoma growth.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-Xylosyl-10-Deacetyltaxol B are characteristic of taxane compounds. The compound has a molecular weight of 921.98 g/mol and a molecular formula of C₄₈H₅₉NO₁₇. As a large, complex natural product, it is expected to have limited oral bioavailability and is typically administered parenterally. The compound is extracted from Taxus species.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 7-Xylosyl-10-Deacetyltaxol B has not been extensively documented. As a taxol derivative with antitumor activity, it may have similar toxicity to other taxanes, including myelosuppression and neurotoxicity. Comprehensive toxicological evaluations would be required for therapeutic development. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
According to reports, 7-xylosyl-10-deacetylated paclitaxel B has been found in Taxus cuspidata, Taxus baccata, and Taxus wallichiana, and relevant data are available for reference.
7-Xylosyl-10-Deacetyltaxol B (CAS# 90332-64-2, molecular formula C₄₈H₅₉NO₁₇, molecular weight 921.98) is a taxol derivative from Taxus species with antitumor activity. It inhibits S180 sarcoma growth. Also known as 7-xylosyl-10-Deacetylpaclitaxel B. No clinical trials or regulatory approvals have been identified. Purity ≥98%. |
| Molecular Formula |
C48H59NO17
|
|---|---|
| Molecular Weight |
921.98
|
| Exact Mass |
921.378
|
| CAS # |
90332-64-2
|
| PubChem CID |
15222311
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1041.3±65.0 °C at 760 mmHg
|
| Flash Point |
583.5±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.638
|
| LogP |
6.39
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
66
|
| Complexity |
1940
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O([C@@]12CO[C@@H]1C[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)[C@]1(C([C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@H](C4C=CC=CC=4)NC(=O)/C(/C)=C/C)C[C@]([C@H]([C@H]21)OC(C1C=CC=CC=1)=O)(O)C3(C)C)O)=O)C)C(=O)C
|
| InChi Key |
YAOWLIDDDUBAEI-ZVZSAYPQSA-N
|
| InChi Code |
InChI=1S/C48H59NO17/c1-8-23(2)41(57)49-33(26-15-11-9-12-16-26)36(54)43(59)63-29-20-48(60)40(65-42(58)27-17-13-10-14-18-27)38-46(7,39(56)35(53)32(24(29)3)45(48,5)6)30(19-31-47(38,22-62-31)66-25(4)50)64-44-37(55)34(52)28(51)21-61-44/h8-18,28-31,33-38,40,44,51-55,60H,19-22H2,1-7H3,(H,49,57)/b23-8+/t28-,29+,30+,31-,33+,34+,35-,36-,37-,38+,40+,44+,46-,47+,48-/m1/s1
|
| Chemical Name |
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,12-dihydroxy-15-[(2R,3S)-2-hydroxy-3-[[(E)-2-methylbut-2-enoyl]amino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-9-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
|
| Synonyms |
7-Xylosyl-10-deacetyltaxol B; 90332-64-2; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,12-dihydroxy-15-[(2R,3S)-2-hydroxy-3-[[(E)-2-methylbut-2-enoyl]amino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-9-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; 10-Deacetyl-7-xylosyltaxol B; YAOWLIDDDUBAEI-ZVZSAYPQSA-N; DEACETYL-7-XYLOSYLCEPHALOMANNINE, 10-(RG); 7-xylosyl-10-deacetyl-taxol B; CHEMBL3398370;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0846 mL | 5.4231 mL | 10.8462 mL | |
| 5 mM | 0.2169 mL | 1.0846 mL | 2.1692 mL | |
| 10 mM | 0.1085 mL | 0.5423 mL | 1.0846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
